José Ramón González Porras-rekin lankidetzan egindako argitalpenak (10)

2019

  1. Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

    Bone Marrow Transplantation

2017

  1. Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis

    PLoS ONE, Vol. 12, Núm. 8

2015

  1. Incidence and risk factors for life-threatening bleeding after allogeneic stem cell transplant

    British Journal of Haematology, Vol. 169, Núm. 5, pp. 719-725

2014

  1. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

    Bone Marrow Transplantation, Vol. 49, Núm. 5, pp. 684-690

2013

  1. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

    Haematologica, Vol. 98, Núm. 3, pp. 437-443

2008

  1. Emergency surgery of the abdominal aorta in a porcine model: Two sequential experiments

    World Journal of Surgery, Vol. 32, Núm. 4, pp. 642-647

2007

  1. Angiogénesis terapéutica en pacientes con isquemia crítica crónica de las extremidades inferiores

    Mapfre medicina, Vol. 18, Núm. 3, pp. 180-189

  2. Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up

    Cytotherapy

  3. Therapeutical angiogenesis in patients with critical leg ischemia. Phase II study with injection of AC133+ cells mobilized with G-CSF from peripheral blood. Follow-up of three first cases

    Mapfre Medicina, Vol. 18, Núm. 3, pp. 180-189

2005

  1. CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Leukemia and Lymphoma, Vol. 46, Núm. 2, pp. 177-183